EUVIMEDObjevte EUVIMED
Video/Audio

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-derived Extracellular Vesicle-based Cancer Biotherapeutics

Frederic St-Denis-Bissonnette, Melanie Kirkby, Lisheng Wang, Jessie R Lavoie

Journal of Visualized Experiments · 2024

DOI: 10.3791/67227 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2024. Written by Frederic St-Denis-Bissonnette and 3 co-authors. Institution: Biologic and Radiopharmaceutical Drugs Directorate; Department of Biochemistry, Microbiology and Immunology Institute, University of Ottawa. Major MEDLINE topics: Killer Cells, Natural, Extracellular Vesicles. Cited 3 times so far (Crossref); 37 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Natural killer cell-derived extracellular vesicles (NK-EVs) are being investigated as cancer biotherapeutics. They possess unique properties as cytotoxic nanovesicles targeting cancer cells and as immunomodulatory communicators. A scalable biomanufacturing workflow enables the production of large quantities of high-purity NK-EVs to meet the pre-clinical and clinical demands. The workflow employs a closed-loop hollow-fiber bioreactor, enabling continuous production of NK-EVs from the NK92-MI cell line under serum-free, xeno-free, feeder-free, and antibiotic-free conditions in compliance with Good Manufacturing Practices standards. This protocol-driven study outlines the biomanufacturing workflow for isolating NK-EVs using size-exclusion chromatography, ultrafiltration, and filter-based sterilization. Essential NK-EV product characterization is performed via nanoparticle tracking analysis, and their functionality is assessed through a validated cell viability-based potency assay against cancer cells. This scalable biomanufacturing process holds significant potential to advance the clinical translation of NK-EV-based cancer biotherapeutics by adhering to best practices and ensuring reproducibility.

Subjects

MeSH terms (MEDLINE)

Killer Cells, NaturalExtracellular VesiclesHumansWorkflowBioreactorsNeoplasmsChromatography, GelCell Line, Tumor

Authors and institutions

  • Biologic and Radiopharmaceutical Drugs Directorate; Department of Biochemistry, Microbiology and Immunology Institute, University of Ottawa.
  • Department of Biochemistry, Microbiology and Immunology Institute, University of Ottawa; Centre for Infection, Immunity and Inflammation Institute, University of Ottawa; Regenerative Medicine Program, Ottawa Hospital Re…
  • Biologic and Radiopharmaceutical Drugs Directorate; Department of Biochemistry, Microbiology and Immunology Institute, University of Ottawa; jessie.lavoie@hc-sc.gc.ca.

Cite

APA

St-Denis-Bissonnette, F., Kirkby, M., Wang, L., & Lavoie, J. R. (2024). Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-derived Extracellular Vesicle-based Cancer Biotherapeutics. Journal of Visualized Experiments. https://doi.org/10.3791/67227

Vancouver

St-Denis-Bissonnette F, Kirkby M, Wang L, Lavoie JR. Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-derived Extracellular Vesicle-based Cancer Biotherapeutics. Journal of Visualized Experiments. 2024. doi:10.3791/67227

BibTeX
@article{StDenisBissonnette2024,
  author = {St-Denis-Bissonnette, Frederic and Kirkby, Melanie and Wang, Lisheng and Lavoie, Jessie R},
  title = {Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-derived Extracellular Vesicle-based Cancer Biotherapeutics},
  journal = {Journal of Visualized Experiments},
  year = {2024},
  doi = {10.3791/67227}
}
Start for free →